Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class? Authors’ reply

S. Bonovas, T. Lytras, G. Nikolopoulos, L. Peyrin-Biroulet, S. Danese
  • Alimentary Pharmacology & Therapeutics (Suppl), January 2018, Wiley
  • DOI: 10.1111/apt.14486
The author haven't yet claimed this publicationThe author haven't yet claimed this publication

In partnership with: